Exploring the pharmacological mechanism of Yanghe Decoction on HER2-positive breast cancer by a network pharmacology approach

Certain Chinese medicine formulae from traditional Chinese Medicine (TCM) are effective for treating and preventing diseases in clinical practice. Yanghe Decoction (YHD) is a Chinese medicine formula that is used to treat breast cancer, especially HER-positive breast cancer; however, the active comp...

Full description

Saved in:
Bibliographic Details
Published in:Journal of ethnopharmacology 2017-03, Vol.199, p.68-85
Main Authors: Zeng, Liuting, Yang, Kailin
Format: Article
Language:English
Subjects:
Antineoplastic Agents, Phytogenic - pharmacology
Antineoplastic Agents, Phytogenic - therapeutic use
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Caco-2 Cells
Chinese medicine formulae
Drugs, Chinese Herbal - pharmacology
Drugs, Chinese Herbal - therapeutic use
Female
Gene Regulatory Networks - drug effects
Gene Regulatory Networks - genetics
HER2-positive breast cancer
Humans
Network pharmacology
Receptor, ErbB-2 - genetics
Traditional Chinese medicine
Yanghe Decoction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Certain Chinese medicine formulae from traditional Chinese Medicine (TCM) are effective for treating and preventing diseases in clinical practice. Yanghe Decoction (YHD) is a Chinese medicine formula that is used to treat breast cancer, especially HER-positive breast cancer; however, the active compounds, potential targets, and pharmacological and molecular mechanism of its action against cancer remain unclear. Therefore, further investigation is required. A network pharmacology approach comprising drug-likeness evaluation, oral bioavailability prediction, Caco-2 permeability prediction, multiple compound target prediction, multiple know target collection, breast cancer genes collection, and network analysis has been used in this study. Four networks are set up, including HER2-positive breast cancer network, compound-compound target network of YHD, YHD-HER2-positive breast cancer network and compound-known target-HER2-positive breast cancer network, and some HER2-positive breast cancer and YHD related targets, clusters, biological processes and pathways are found. We also found some potential anti-cancer compounds. Our works successfully predict, illuminate and confirm the molecular synergy of YHD for HER2-positive breast cancer and found the potential HER2-positive breast cancer associated targets, cluster, biological processes and pathways. This study not only provide clues to the researcher who explores pharmacological and molecular mechanism of YHD acting on HER2-positive breast cancer, but also demonstrates a feasible method for discovering potential drugs from Chinese medicine formulae. [Display omitted]
ISSN:0378-8741
1872-7573
DOI:10.1016/j.jep.2017.01.045